{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-25-000050","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2025-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.091811+00:00","generated_at":"2026-05-20T01:12:42.783861+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiora grants Senju exclusive option for KIO-301 in Asia; $1.25M upfront, up to $110M milestones plus royalties","bullets":["Immediate $1.25M option payment; if exercised, mid-single-digit million upfront and up to $110M in development, regulatory, and commercial milestones.","Tiered royalties from high single-digit to high teen percent on net sales; territory covers Japan, China, and other key Asian countries.","Option exercisable after topline data from ongoing ABACUS-2 Phase 2 trial; Senju to collaborate with Théa, Kiora's ex-Asia partner.","Combined deal value with Théa (2024) and Senju exceeds $400M plus royalties; cash runway extended into late 2027.","KIO-301 is a molecular photoswitch for retinitis pigmentosa and other inherited retinal diseases, currently in Phase 2."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-25-000050","json":"https://secwatch.observer/filing/0001372514-25-000050.json","markdown":"https://secwatch.observer/filing/0001372514-25-000050.md","text":"https://secwatch.observer/filing/0001372514-25-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251425000050/0001372514-25-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251425000050/kprx-20250530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T01:12:42.783861+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}